Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire•01/10/2026•16:05 ET
0
Key Highlights
- ➤Karyopharm (KPTI) granted 333 restricted stock units to one newly-hired employee
- ➤RSU award vests over three years, with 33 1/3% annually
- ➤Grant issued under Nasdaq Listing Rule 5635(c)(4) as an employment inducement
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of September 30, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Get started
Create a free account to read the full story.